| 2737 | Humans |
| 1600 | Female |
| 1448 | Male |
| 935 | Middle Aged |
| 863 | Adult |
| 842 | Animals |
| 737 | Aged |
| 377 | Young Adult |
| 339 | Adolescent |
| 335 | Treatment Outcome |
| 305 | Risk Factors |
| 272 | Aged, 80 and over |
| 221 | Child |
| 207 | Mice |
| 191 | Time Factors |
| 179 | Prospective Studies |
| 157 | Follow-Up Studies |
| 155 | Case-Control Studies |
| 152 | Prognosis |
| 150 | Mutation |
| 143 | Child, Preschool |
| 138 | Genotype |
| 135 | Cohort Studies |
| 134 | Polymorphism, Single Nucleotide |
| 131 | Genetic Predisposition to Disease |
| 123 | Phenotype |
| 122 | Infant |
| 120 | Double-Blind Method |
| 118 | Phylogeny |
| 113 | Genome-Wide Association Study |
| 110 | Disease-Free Survival |
| 108 | Retrospective Studies |
| 95 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 94 | Incidence |
| 94 | Europe |
| 94 | Age Factors |
| 90 | Reproducibility of Results |
| 90 | Mice, Inbred C57BL |
| 90 | Ecosystem |
| 90 | Australia |
| 87 | Severity of Illness Index |
| 86 | Practice Guidelines as Topic |
| 79 | Proportional Hazards Models |
| 79 | Consensus |
| 77 | Disease Progression |
| 76 | Disease Models, Animal |
| 75 | Surveys and Questionnaires |
| 75 | Genetic Variation |
| 72 | Breast Neoplasms (genetics) |
| 71 | Pregnancy |
| 71 | Infant, Newborn |
| 70 | Survival Rate |
| 70 | Molecular Sequence Data |
| 69 | Risk Assessment |
| 69 | Kaplan-Meier Estimate |
| 68 | Prevalence |
| 66 | Sequence Analysis, DNA |
| 65 | Signal Transduction |
| 65 | Risk |
| 65 | Neoplasm Staging |
| 65 | Cross-Sectional Studies |
| 65 | Biodiversity |
| 65 | Antineoplastic Agents (therapeutic use) |
| 63 | Algorithms |
| 60 | Models, Biological |
| 60 | Amino Acid Sequence |
| 59 | Models, Theoretical |
| 57 | Evolution, Molecular |
| 56 | Mice, Knockout |
| 56 | Alleles |
| 55 | Survival Analysis |
| 55 | Registries |
| 54 | Odds Ratio |
| 54 | Drug Administration Schedule |
| 54 | Cell Line, Tumor |
| 54 | Biological Evolution |
| 53 | Randomized Controlled Trials as Topic |
| 53 | International Cooperation |
| 51 | Societies, Medical |
| 51 | Polymorphism, Single Nucleotide (genetics) |
| 51 | Multivariate Analysis |
| 51 | Global Health |
| 51 | Europe (epidemiology) |
| 50 | Gene Expression Profiling |
| 49 | Quality of Life |
| 49 | Predictive Value of Tests |
| 49 | Pedigree |
| 48 | Species Specificity |
| 48 | Genetic Association Studies |
| 48 | Drug Therapy, Combination |
| 48 | Cells, Cultured |
| 48 | Body Mass Index |
| 48 | Biomarkers (blood) |
| 46 | Longitudinal Studies |
| 46 | Breast Neoplasms (pathology) |
| 45 | Sex Factors |
| 45 | European Continental Ancestry Group (genetics) |
| 45 | Cell Line |
| 44 | Terminology as Topic |
| 44 | Mutation (genetics) |
| 44 | France |
| 44 | Combined Modality Therapy |
| 44 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 43 | Magnetic Resonance Imaging |
| 43 | Internationality |
| 42 | Dose-Response Relationship, Drug |
| 41 | Sensitivity and Specificity |
| 40 | Models, Molecular |
| 40 | Genetic Predisposition to Disease (genetics) |
| 39 | Australia (epidemiology) |
| 38 | Recurrence |
| 38 | Logistic Models |
| 38 | Comorbidity |
| 37 | Seasons |
| 37 | Rats |
| 37 | Disease Management |
| 36 | Neoplasm Metastasis |
| 36 | Gene Expression Regulation |
| 36 | Computer Simulation |
| 36 | Climate Change |
| 36 | Chromosome Mapping |
| 35 | Base Sequence |
| 34 | Temperature |
| 34 | Protein Binding |
| 33 | Breast Neoplasms (drug therapy) |
| 33 | Antineoplastic Agents (adverse effects) |
| 32 | Research Design |
| 32 | Evidence-Based Medicine |
| 32 | Clinical Trials as Topic |
| 32 | Biomechanical Phenomena |
| 31 | United States |
| 31 | Protein Kinase Inhibitors (therapeutic use) |
| 31 | Mice, Transgenic |
| 31 | Melanoma (drug therapy) |
| 31 | Immunohistochemistry |
| 31 | DNA Mutational Analysis |
| 30 | Transcription Factors (genetics) |
| 30 | Models, Statistical |
| 30 | Coral Reefs |
| 29 | Diet |
| 29 | Climate |
| 29 | Antiviral Agents (therapeutic use) |
| 28 | Software |
| 28 | Heterozygote |
| 28 | Bayes Theorem |
| 28 | Age of Onset |
| 27 | Skin Neoplasms (pathology) |
| 27 | Outcome Assessment (Health Care) |
| 27 | Melanoma (pathology) |
| 27 | High-Throughput Nucleotide Sequencing |
| 27 | HIV Infections (drug therapy) |
| 27 | HEK293 Cells |
| 27 | Environment |
| 27 | Breast Neoplasms (metabolism) |
| 27 | Administration, Oral |
| 26 | Ovarian Neoplasms (pathology) |
| 26 | Genomics |
| 26 | Databases, Factual |
| 25 | Signal Transduction (genetics) |
| 25 | Life Style |
| 25 | Intensive Care Units |
| 25 | Intellectual Disability (genetics) |
| 25 | Gene Frequency |
| 25 | Gene Expression |
| 24 | Protein Kinase Inhibitors (adverse effects) |
| 24 | Neoplasm Grading |
| 24 | Models, Genetic |
| 24 | Guidelines as Topic |
| 24 | Equipment Design |
| 24 | Electromyography |
| 24 | Chronic Disease |
| 24 | Brain (pathology) |
| 23 | Transcriptome |
| 23 | Socioeconomic Factors |
| 23 | Quantitative Trait Loci |
| 23 | Plant Proteins (genetics) |
| 23 | Ovarian Neoplasms (genetics) |
| 23 | Muscle, Skeletal (physiology) |
| 23 | Hepatitis C, Chronic (drug therapy) |
| 23 | Conservation of Natural Resources (methods) |
| 23 | Cluster Analysis |
| 23 | Antibodies, Monoclonal (therapeutic use) |
| 22 | Real-Time Polymerase Chain Reaction |
| 22 | RNA, Messenger (genetics) |
| 22 | Protein Transport |
| 22 | Protein Conformation |
| 22 | Oceans and Seas |
| 22 | Melanoma (genetics) |
| 22 | Genetic Loci |
| 22 | Gene Expression Regulation, Plant |
| 22 | Gene Expression Regulation, Neoplastic |
| 22 | Critical Illness |
| 22 | Computational Biology |
| 22 | Chemotherapy, Adjuvant |
| 21 | Tomography, X-Ray Computed |
| 21 | Regression Analysis |
| 21 | RNA, Messenger (metabolism) |
| 21 | Pilot Projects |
| 21 | Neuropsychological Tests |
| 21 | Linear Models |
| 21 | Genetics, Population |
| 21 | Flow Cytometry |
| 21 | Exercise (physiology) |
| 21 | Conservation of Natural Resources |
| 21 | Cell Differentiation |
| 21 | Breast Neoplasms (epidemiology) |
| 21 | Biomass |
| 21 | Antineoplastic Agents (administration & dosage) |
| 21 | Acute Disease |
| 20 | Survival Rate (trends) |
| 20 | Stress, Physiological |
| 20 | Risk Assessment (methods) |
| 20 | Remission Induction |
| 20 | Prosthesis Design |
| 20 | Population Dynamics |
| 20 | Observer Variation |
| 20 | Neoplasms (pathology) |
| 20 | Neoplasms (drug therapy) |
| 20 | Mutation, Missense |
| 20 | Membrane Proteins (genetics) |
| 20 | Hospital Mortality |
| 20 | Haplotypes |
| 20 | Feeding Behavior |
| 20 | Cooperative Behavior |
| 20 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 20 | Anti-Bacterial Agents (therapeutic use) |
| 20 | Analysis of Variance |
| 19 | Reverse Transcriptase Polymerase Chain Reaction |
| 19 | Plant Proteins (metabolism) |
| 19 | Phosphorylation |
| 19 | Neoplasms (epidemiology) |
| 19 | Meta-Analysis as Topic |
| 19 | Imidazoles (administration & dosage) |
| 19 | Hydrogen-Ion Concentration |
| 19 | Hepacivirus (genetics) |
| 19 | Geography |
| 19 | France (epidemiology) |
| 19 | Exercise |
| 19 | Electrocardiography |
| 19 | Databases, Genetic |
| 19 | DNA, Mitochondrial (genetics) |
| 19 | DNA Methylation |
| 19 | Blotting, Western |
| 19 | Binding Sites |
| 19 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 18 | Viral Load |
| 18 | United Kingdom |
| 18 | Stroke (epidemiology) |
| 18 | Sequence Alignment |
| 18 | Running (physiology) |
| 18 | Patient Selection |
| 18 | Medical Oncology |
| 18 | Magnetic Resonance Imaging (methods) |
| 18 | Lung Neoplasms (pathology) |
| 18 | Host-Pathogen Interactions |
| 18 | Health Knowledge, Attitudes, Practice |
| 18 | Genome, Human (genetics) |
| 18 | Exome (genetics) |
| 18 | DNA-Binding Proteins (genetics) |
| 18 | Colorectal Neoplasms (genetics) |
| 18 | Cattle |
| 18 | Cardiovascular Diseases (prevention & control) |
| 18 | Brain (metabolism) |
| 18 | Biomarkers, Tumor (genetics) |
| 18 | Antineoplastic Agents (pharmacology) |
| 17 | Transcription Factors (metabolism) |
| 17 | Stroke (etiology) |
| 17 | Skin Neoplasms (genetics) |
| 17 | Skin Neoplasms (drug therapy) |
| 17 | Signal Transduction (drug effects) |
| 17 | Neoplasm Recurrence, Local (drug therapy) |
| 17 | Mitochondria (metabolism) |
| 17 | Mice, Inbred BALB C |
| 17 | Kinetics |
| 17 | Genome, Plant |
| 17 | Fossils |
| 17 | Exercise Test |
| 17 | Drug Combinations |
| 17 | Colorectal Neoplasms (pathology) |
| 17 | Cell Proliferation |
| 17 | Cardiovascular Diseases (epidemiology) |
| 17 | Body Weight |
| 17 | Biopsy |
| 17 | Athletes |
| 17 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 17 | Aging (physiology) |
| 17 | Age Distribution |
| 16 | Transcription, Genetic |
| 16 | T-Lymphocytes (immunology) |
| 16 | Sex Distribution |
| 16 | Sex Characteristics |
| 16 | Reference Values |
| 16 | ROC Curve |
| 16 | Phylogeography |
| 16 | Molecular Sequence Annotation |
| 16 | Hypoglycemic Agents (therapeutic use) |
| 16 | History, Ancient |
| 16 | Germ-Line Mutation |
| 16 | Genomics (methods) |
| 16 | Genome-Wide Association Study (methods) |
| 16 | Enzyme-Linked Immunosorbent Assay |
| 16 | Droughts |
| 16 | Body Size |
| 16 | Blood Glucose (metabolism) |
| 16 | Biomarkers (metabolism) |
| 16 | Athletic Performance (physiology) |
| 16 | Asian Continental Ancestry Group (genetics) |
| 16 | Animal Distribution |
| 15 | Vaccination |
| 15 | Sulfonamides (therapeutic use) |
| 15 | Structure-Activity Relationship |
| 15 | Social Behavior |
| 15 | Receptor, ErbB-2 (metabolism) |
| 15 | Rats, Wistar |
| 15 | Quantitative Trait Loci (genetics) |
| 15 | Protein Kinase Inhibitors (administration & dosage) |
| 15 | Postmenopause |
| 15 | Positron-Emission Tomography |
| 15 | Polymerase Chain Reaction |
| 15 | Plant Leaves (metabolism) |
| 15 | Neoplasms (therapy) |
| 15 | Neoplasms (genetics) |
| 15 | Muscle, Skeletal (physiopathology) |
| 15 | Multiple Myeloma (drug therapy) |
| 15 | Monte Carlo Method |
| 15 | Melanoma (mortality) |
| 15 | MCF-7 Cells |
| 15 | Injections, Subcutaneous |
| 15 | Forecasting |
| 15 | Diagnosis, Differential |
| 15 | Diabetes Mellitus, Type 2 (drug therapy) |
| 15 | Developing Countries |
| 15 | Delphi Technique |
| 15 | Cost-Benefit Analysis |
| 15 | Cause of Death |
| 15 | Brain (diagnostic imaging) |
| 15 | Bone Neoplasms (secondary) |
| 15 | Blood Pressure |
| 15 | BRCA1 Protein (genetics) |
| 14 | Water |
| 14 | United States (epidemiology) |
| 14 | Repressor Proteins (genetics) |
| 14 | Rats, Sprague-Dawley |
| 14 | Prostatic Neoplasms (genetics) |
| 14 | Paclitaxel (administration & dosage) |
| 14 | Ovarian Neoplasms (therapy) |
| 14 | Ovarian Neoplasms (drug therapy) |
| 14 | Organ Size |
| 14 | Nuclear Proteins (genetics) |
| 14 | Muscle Contraction (physiology) |
| 14 | HeLa Cells |
| 14 | HIV Infections (complications) |
| 14 | Fishes |
| 14 | Epigenesis, Genetic |
| 14 | Diabetes Mellitus, Type 2 (complications) |
| 14 | Crystallography, X-Ray |
| 14 | Congresses as Topic |
| 14 | Clinical Trials, Phase III as Topic |
| 14 | Carbon Cycle |
| 14 | Biomarkers, Tumor (metabolism) |
| 14 | Biomarkers, Tumor (analysis) |
| 14 | Arabidopsis (metabolism) |
| 14 | Arabidopsis (genetics) |
| 14 | Antibodies, Monoclonal (administration & dosage) |
| 14 | Anti-Bacterial Agents (administration & dosage) |
| 14 | Adaptation, Physiological |
| 13 | World Health Organization |
| 13 | Tumor Suppressor Proteins (genetics) |
| 13 | Tropical Climate |
| 13 | Swine |
| 13 | Selection, Genetic |
| 13 | Receptors, Estrogen (metabolism) |
| 13 | Pyrimidines (therapeutic use) |
| 13 | Proteins (genetics) |
| 13 | Prostatic Neoplasms, Castration-Resistant (pathology) |
| 13 | Prostatic Neoplasms (pathology) |
| 13 | Population Density |
| 13 | Pain Measurement |
| 13 | Muscle, Skeletal (metabolism) |
| 13 | Microbial Sensitivity Tests |
| 13 | Lung Neoplasms (genetics) |
| 13 | Light |
| 13 | Internet |
| 13 | Homeodomain Proteins (genetics) |
| 13 | Hepatitis C, Chronic (complications) |
| 13 | Hematopoietic Stem Cell Transplantation |
| 13 | Healthy Volunteers |
| 13 | Health Policy |
| 13 | Genome |
| 13 | Genome, Human |
| 13 | Genetic Variation (genetics) |
| 13 | Genetic Testing |
| 13 | Genetic Loci (genetics) |
| 13 | Gene-Environment Interaction |
| 13 | Feasibility Studies |
| 13 | European Continental Ancestry Group |
| 13 | Elasticity Imaging Techniques |
| 13 | Computational Biology (methods) |
| 13 | Cholesterol (metabolism) |
| 13 | Carrier Proteins (genetics) |
| 13 | Carbon (metabolism) |
| 13 | Calcium (metabolism) |
| 13 | Brain (physiopathology) |
| 13 | Blood Pressure (physiology) |
| 13 | Bacterial Proteins (genetics) |
| 13 | Arthritis, Rheumatoid (drug therapy) |
| 13 | Arabidopsis Proteins (metabolism) |
| 13 | Antiviral Agents (adverse effects) |
| 13 | Antiviral Agents (administration & dosage) |
| 13 | Antibodies, Monoclonal (adverse effects) |
| 13 | Amino Acid Substitution |
| 12 | Syndrome |
| 12 | Stroke Volume |
| 12 | Smoking (epidemiology) |
| 12 | Sheep |
| 12 | Sequence Analysis, RNA |
| 12 | Ribavirin (therapeutic use) |
| 12 | Reference Standards |
| 12 | Reactive Oxygen Species (metabolism) |
| 12 | Pyrimidines (administration & dosage) |
| 12 | Proto-Oncogene Proteins B-raf (genetics) |
| 12 | Promoter Regions, Genetic |
| 12 | Practice Guidelines as Topic (standards) |
| 12 | Oxygen Consumption |
| 12 | Oxidation-Reduction |
| 12 | Oligonucleotide Array Sequence Analysis |
| 12 | North America |
| 12 | Neurons (metabolism) |
| 12 | Neoplasms (immunology) |
| 12 | Neoplasm Recurrence, Local (pathology) |
| 12 | Neoplasm Invasiveness |
| 12 | Macrophages (metabolism) |
| 12 | Liver (metabolism) |
| 12 | Killer Cells, Natural (immunology) |
| 12 | Kidney Neoplasms (pathology) |
| 12 | Immunosuppressive Agents (therapeutic use) |
| 12 | Imidazoles (therapeutic use) |
| 12 | Imaging, Three-Dimensional |
| 12 | Hypertension, Pulmonary (physiopathology) |
| 12 | Hospitalization |
| 12 | Hepatitis C, Chronic (virology) |
| 12 | Hemodynamics |
| 12 | Glucose (metabolism) |
| 12 | Global Health (trends) |
| 12 | Genetic Markers |
| 12 | Forests |
| 12 | Food Chain |
| 12 | Extinction, Biological |
| 12 | Estrogen Receptor alpha (genetics) |
| 12 | Electroencephalography |
| 12 | Dendritic Cells (immunology) |
| 12 | Cost of Illness |
| 12 | Consensus Development Conferences as Topic |
| 12 | Cognition |
| 12 | Cholesterol, LDL (blood) |
| 12 | Cell Proliferation (drug effects) |
| 12 | Cardiovascular Diseases (blood) |
| 12 | Breast Neoplasms (mortality) |
| 12 | Brain (physiology) |
| 12 | Biomarkers |
| 12 | Bacterial Proteins (metabolism) |
| 12 | Area Under Curve |
| 12 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 12 | Anti-HIV Agents (therapeutic use) |
| 12 | Administration, Intravenous |
| 11 | Up-Regulation |
| 11 | Triticum (genetics) |
| 11 | T-Lymphocytes, Regulatory (immunology) |
| 11 | Stroke (therapy) |
| 11 | Stroke (drug therapy) |
| 11 | Stents |
| 11 | Statistics as Topic |
| 11 | Soil (chemistry) |
| 11 | Smoking (adverse effects) |
| 11 | Reproduction |
| 11 | Radiography |
| 11 | Proteomics |
| 11 | Prostatic Neoplasms, Castration-Resistant (drug therapy) |
| 11 | Polymorphism, Genetic |
| 11 | Polyethylene Glycols (administration & dosage) |
| 11 | Plant Leaves (physiology) |
| 11 | New Zealand (epidemiology) |
| 11 | Nerve Tissue Proteins (genetics) |
| 11 | Melanoma (secondary) |
| 11 | Lymphocyte Activation |
| 11 | Lymphatic Metastasis |
| 11 | Liver (pathology) |
| 11 | Lipids (blood) |
| 11 | Introduced Species |
| 11 | International Agencies |
| 11 | Indoles (administration & dosage) |
| 11 | In Situ Hybridization, Fluorescence |
| 11 | Imidazoles (adverse effects) |
| 11 | Hot Temperature |
| 11 | Host-Parasite Interactions |
| 11 | Homozygote |
| 11 | High-Throughput Nucleotide Sequencing (methods) |
| 11 | Health Services Accessibility |
| 11 | Global Health (statistics & numerical data) |
| 11 | Genes, BRCA2 |
